Abiopharma

Global Investments Limited (“GIL” or the “Company”) is a mutual fund company incorporated in Bermuda and listed on the Main Board of Singapore Exchange Securities Trading Limited (“SGX-ST”).
 
The Company’s investment policy is to make investments in a portfolio of assets in different sectors through different means which include but are not limited to direct asset ownership, swaps, debts, warrants, options, convertibles, preference shares, equity, guarantees of assets and performance, securities lending and participating loan agreements provided that it will not make any direct investments in real estate and commodities.
 
The Company’s strategy is to actively manage and grow its assets with the focus to protect and grow value. It aims to grow its assets and seek investment in assets that will generate steady income and potential appreciation in capital to deliver regular dividends and achieve capital growth.
 
The board of directors is responsible for the Company’s strategic goals and corporate governance, and making investment and divestment decisions based on recommendation of  Singapore Consortium Investment Management Limited (“SICIM” or the “Manager”). The majority of the Board comprises independent directors.
 
The Company is managed by SICIM, a Singapore incorporated company which holds a capital markets services licence for fund management issued by the Monetary Authority of Singapore.

Additional info from SGX:

Global Investments Limited (“GIL” or the “Company”) is a mutual fund company incorporated in Bermuda and listed on the Main Board of Singapore Exchange Securities Trading Limited (“SGX-ST”).
 
The Company’s investment policy is to make investments in a portfolio of assets in different sectors through different means which include but are not limited to direct asset ownership, swaps, debts, warrants, options, convertibles, preference shares, equity, guarantees of assets and performance, securities lending and participating loan agreements provided that it will not make any direct investments in real estate and commodities.
 
The Company’s strategy is to actively manage and grow its assets with the focus to protect and grow value. It aims to grow its assets and seek investment in assets that will generate steady income and potential appreciation in capital to deliver regular dividends and achieve capital growth.
 
The board of directors is responsible for the Company’s strategic goals and corporate governance, and making investment and divestment decisions based on recommendation of  Singapore Consortium Investment Management Limited (“SICIM” or the “Manager”). The majority of the Board comprises independent directors.
 
The Company is managed by SICIM, a Singapore incorporated company which holds a capital markets services licence for fund management issued by the Monetary Authority of Singapore.